Abstract
Macrophage migration inhibitory factor (MIF), a cytokine involved in the pathogenesis of sepsis, diabetes, asthma, arthritis, and cancer, has an enzymatic active site that has proven to be an effective target for small molecule-based inhibitors. Herein, we describe the synthesis of a novel arylazoarylmethane compound (3) from a known arylhydrazone MIF inhibitor (2). This new compound has improved stability and in vivo biological activity.
Keywords:
Arylazoarylmethane; Arylhydrazone; Inflammation; Macrophage migration inhibitory factor.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Inflammatory Agents / chemical synthesis*
-
Anti-Inflammatory Agents / pharmacology*
-
Carrageenan
-
Disease Models, Animal
-
Drug Design
-
Drug Stability
-
Enzyme Inhibitors / chemical synthesis*
-
Enzyme Inhibitors / pharmacology*
-
Hydrazones / chemical synthesis*
-
Hydrazones / pharmacology*
-
Inflammation / chemically induced
-
Inflammation / enzymology
-
Inflammation / prevention & control
-
Intramolecular Oxidoreductases / antagonists & inhibitors
-
Intramolecular Oxidoreductases / metabolism
-
Macrophage Migration-Inhibitory Factors / antagonists & inhibitors*
-
Macrophage Migration-Inhibitory Factors / metabolism
-
Mice
-
Molecular Structure
-
Structure-Activity Relationship
Substances
-
Anti-Inflammatory Agents
-
Enzyme Inhibitors
-
Hydrazones
-
Macrophage Migration-Inhibitory Factors
-
Carrageenan
-
Intramolecular Oxidoreductases
-
Mif protein, mouse